Anúncio
Anúncio

ABOS

ABOS logo

Acumen Pharmaceuticals, Inc. Common Stock

1.96
USD
Patrocinado
-0.02
-0.86%
06 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

1.98

+0.02
+0.92%

Relatórios de Lucros ABOS

Rácio de surpresa positiva

ABOS separação 7 de 18 últimas estimativas.

39%

Próximo Relatório

Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.46
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+4.55%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-25.81%

Acumen Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, ABOS reported earnings of -0.44 USD per share (EPS) for Q3 25, beating the estimate of -0.61 USD, resulting in a 28.54% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.02% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.46 USD, with revenue projected to reach -- USD, implying an aumentar of 4.55% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, Acumen Pharmaceuticals, Inc. Common Stock reported EPS of -$0.44, beating estimates by 28.54%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.02%, changed from $1.97 before the earnings release to $1.95 the day after.
The next earning report is scheduled for 25 de mar. de 2026.
Based on 8 analistas, Acumen Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.46 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio